Preclinical safety

14/04/2025Uncategorized

Allegro demonstrates safety profile of osteoarthritis hydrogel in data presentation at World Congress on Osteoporosis

Liege, Belgium – 11 April 2025 (17:00 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]

25/03/2025Uncategorized

Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies

Liege, Belgium – 25 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]

04/03/2025Uncategorized

Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies

Liege, Belgium – 4 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint […]

11/12/202411/12/2024Uncategorized

Allegro’s osteoarthritis injectable shock absorbing gel demonstrates preclinical safety

Liege, Belgium – 11 December 2024 (07:30 CET) – Allegro NV, a biomedical companydeveloping transformative nanotechnology-based devices for degenerative joint disease, todayannounced […]